MX349293B - Tratamiento de cancer con dosis elevadas de proteinas de fusion del receptor del factor de crecimiento de fibroblastos 1 (fgfr1) solubles. - Google Patents

Tratamiento de cancer con dosis elevadas de proteinas de fusion del receptor del factor de crecimiento de fibroblastos 1 (fgfr1) solubles.

Info

Publication number
MX349293B
MX349293B MX2013005387A MX2013005387A MX349293B MX 349293 B MX349293 B MX 349293B MX 2013005387 A MX2013005387 A MX 2013005387A MX 2013005387 A MX2013005387 A MX 2013005387A MX 349293 B MX349293 B MX 349293B
Authority
MX
Mexico
Prior art keywords
cancer
treatment
fusion proteins
patient
growth factor
Prior art date
Application number
MX2013005387A
Other languages
English (en)
Other versions
MX2013005387A (es
Inventor
Keer Harold
Original Assignee
Five Prime Therapeutics Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc * filed Critical Five Prime Therapeutics Inc *
Publication of MX2013005387A publication Critical patent/MX2013005387A/es
Publication of MX349293B publication Critical patent/MX349293B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a métodos para tratar un paciente que padece de cáncer que comprende administrar al paciente una proteína de fusión soluble del receptor de factor de crecimiento de fibroblastos 1 (FGR!), como un dominio extracelular de un polipéptido de FGFR1, unido a un polipéptido de Fc u otro compañero de fusión. La proteína de fusión puede ser administrada en una dosis de al menos alrededor de 2 mg/kg de peso corporal. En algunas modalidades, el paciente tiene una concentración del factor de crecimiento de fibroblastos 2 (FGF-2) en el Plasma de al menos 6 pg/ml. En algunas modalidades, el cáncer se caracteriza por un receptor del factor de crecimiento de fibroblastos 2 (FGFR2) que posee una mutación activadora dependiente de ligandos.
MX2013005387A 2010-11-15 2011-11-14 Tratamiento de cancer con dosis elevadas de proteinas de fusion del receptor del factor de crecimiento de fibroblastos 1 (fgfr1) solubles. MX349293B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41394010P 2010-11-15 2010-11-15
US42146210P 2010-12-09 2010-12-09
PCT/US2011/060661 WO2012068030A1 (en) 2010-11-15 2011-11-14 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins

Publications (2)

Publication Number Publication Date
MX2013005387A MX2013005387A (es) 2013-10-17
MX349293B true MX349293B (es) 2017-07-21

Family

ID=44993965

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013005387A MX349293B (es) 2010-11-15 2011-11-14 Tratamiento de cancer con dosis elevadas de proteinas de fusion del receptor del factor de crecimiento de fibroblastos 1 (fgfr1) solubles.
MX2013005388A MX2013005388A (es) 2010-11-15 2011-11-14 Terapias de combinadas de dominio extracelular del receptor del factor de crecimiento de fibroblastos 1 (fgfr1).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013005388A MX2013005388A (es) 2010-11-15 2011-11-14 Terapias de combinadas de dominio extracelular del receptor del factor de crecimiento de fibroblastos 1 (fgfr1).

Country Status (14)

Country Link
EP (2) EP2640377B1 (es)
JP (4) JP6178240B2 (es)
KR (3) KR20130124513A (es)
CN (2) CN107050426A (es)
AU (2) AU2011329127B2 (es)
BR (2) BR112013012041A2 (es)
CA (2) CA2817537A1 (es)
EA (2) EA025828B1 (es)
IL (2) IL226252B (es)
MX (2) MX349293B (es)
NZ (4) NZ610538A (es)
SG (2) SG190248A1 (es)
WO (2) WO2012068032A1 (es)
ZA (2) ZA201303501B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
CA2908391A1 (en) * 2013-05-01 2014-11-06 Five Prime Therapeutics, Inc. Methods of treating cancer
WO2014190147A2 (en) * 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
NZ715667A (en) * 2013-07-05 2022-02-25 Stellar Biome Inc Oral compositions
WO2015066452A2 (en) * 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
CA3010623A1 (en) * 2016-02-04 2017-08-10 Jinsong Ni Antibody-drug synergism technology for treating diseases

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
DE69033109T2 (de) 1989-07-06 1999-11-18 The Regents Of The University Of California, Oakland Rezeptoren für fibroblasten-wachstumsfaktoren
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU662107B2 (en) 1990-07-06 1995-08-24 Aventis Pharmaceuticals Inc. Fibroblast growth factor receptors
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
RO119721B1 (ro) 1992-10-28 2005-02-28 Genentech Inc. Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP1787999B1 (en) 1997-04-07 2010-08-04 Genentech, Inc. Anti-VEGF antibodies
ATE314395T1 (de) 1997-04-07 2006-01-15 Genentech Inc Humanisierte antikörper und verfahren zu ihrer herstellung
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
RU2292221C2 (ru) 2000-06-23 2007-01-27 Шеринг Акциенгезельшафт Комбинации и композиции, которые оказывают воздействие на функцию систем vegf/ рецептор vegf и ангиопоэтин/рецептор tie (ii), и их применение
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP2246333B1 (en) 2003-05-22 2012-10-24 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
EP2248829A1 (en) 2003-05-30 2010-11-10 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
JP2008528033A (ja) 2005-01-27 2008-07-31 ファイブ プライム セラピューティクス， インコーポレイテッド ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
CL2007003411A1 (es) * 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
ZA200903134B (en) * 2006-11-28 2010-08-25 Centelion Modified soluble FGF receptor FC fusions with improved biological activity
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
PL2498799T3 (pl) * 2009-11-13 2017-03-31 Five Prime Therapeutics, Inc. Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2

Also Published As

Publication number Publication date
EA201390716A1 (ru) 2014-02-28
CN103347514B (zh) 2017-02-08
ZA201303573B (en) 2016-07-27
CA2817537A1 (en) 2012-05-24
KR101910779B1 (ko) 2018-10-22
JP5945277B2 (ja) 2016-07-05
EA025828B1 (ru) 2017-02-28
BR112013012040A2 (pt) 2016-08-16
AU2011329127B2 (en) 2015-09-03
CA2817583A1 (en) 2012-05-24
EP2640406A1 (en) 2013-09-25
IL226248A0 (en) 2013-07-31
JP2013543870A (ja) 2013-12-09
JP2017019843A (ja) 2017-01-26
NZ703786A (en) 2016-08-26
NZ703919A (en) 2016-04-29
SG190788A1 (en) 2013-07-31
KR20180053420A (ko) 2018-05-21
NZ610538A (en) 2015-02-27
IL226252A0 (en) 2013-07-31
EP2640377B1 (en) 2018-12-26
AU2011329127A1 (en) 2013-05-02
ZA201303501B (en) 2016-07-27
SG190248A1 (en) 2013-06-28
NZ610487A (en) 2015-03-27
BR112013012041A2 (pt) 2016-11-08
WO2012068032A1 (en) 2012-05-24
CN103347514A (zh) 2013-10-09
JP2014500873A (ja) 2014-01-16
KR20130114676A (ko) 2013-10-18
WO2012068030A1 (en) 2012-05-24
AU2011329125A1 (en) 2013-05-02
IL226252B (en) 2018-05-31
EA201390722A1 (ru) 2013-11-29
JP2016196475A (ja) 2016-11-24
EP2640377A1 (en) 2013-09-25
MX2013005387A (es) 2013-10-17
AU2011329125B2 (en) 2015-07-30
KR20130124513A (ko) 2013-11-14
MX2013005388A (es) 2013-11-04
CN107050426A (zh) 2017-08-18
JP6178240B2 (ja) 2017-08-09

Similar Documents

Publication Publication Date Title
MX349293B (es) Tratamiento de cancer con dosis elevadas de proteinas de fusion del receptor del factor de crecimiento de fibroblastos 1 (fgfr1) solubles.
US11180531B2 (en) Bicyclic peptide ligands specific for Nectin-4
Wang et al. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti‐CTLA‐4 therapy to inhibit cancer metastasis
TW201129373A (en) Methods and compositions using FGF23 fusion polypeptides
HRP20151172T1 (hr) Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
CN105980400A (zh) 生长分化因子15(gdf-15)构建体
EA035559B1 (ru) Связывающиеся с egfr и c-met молекулы с доменами фибронектина типа iii
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
KR20190124247A (ko) Csf1r-기반 키메라 단백질
MX2021005560A (es) Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l).
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
AR090972A1 (es) Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf
JP2014500873A5 (es)
KR20100031123A (ko) Ｖｅｇｆ 억제제 및 이리노테칸을 함유하는 항종양 조합물
MX2014004132A (es) Señuelos humanos notch1.
EA200870535A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ С ИСПОЛЬЗОВАНИЕМ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
PT2285416E (pt) Conjugados para o tratamento de mesotelioma
JP2021515779A (ja) Ｅｇｆｒ抗体によるｃｄ４７遮断療法における改善
Jia et al. ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy
CN108290930A (zh) Pink1 c末端结构域多肽及其用于癌症治疗的方法
CN102070712B (zh) Vegf-a蛋白及其用途
PL233352B1 (pl) Przeciwnowotworowe białko fuzyjne
Ferrari et al. SUBSTANCE P EXPRESSION AND ITS INHIBITION IN CORNEAL NEOVASCULARIZATION

Legal Events

Date Code Title Description
FG Grant or registration